Fox Chase Cancer Center News

PHILADELPHIA (February 10, 2020)—Its involvement in causing over 50 percent of all cancers makes p53 one of the most well-known cancer genes. But there are some malignancies, like kidney cancer, that rarely have p53 mutations.

PHILADELPHIA (February 5, 2020) –Roland L. Dunbrack Jr., PhD, director of the Molecular Modeling Facility at Fox Chase Cancer Center, and his team have updated their Protein Common Interface Database (ProtCID) to include data on the individual domain level, which greatly increases the number of large protein-protein clusters available in the database.

PHILADELPHIA (February 4, 2020) – Fox Chase Cancer Center has announced that its Nurse Residency Program achieved ANCC Practice Transition Accreditation with Distinction, the highest recognition awarded.

PHILADELPHIA (February 3, 2020) – Although insulin-like growth factor receptor-1 (IGF-R1) is a biomarker for wild-type gastrointestinal stromal tumors (GIST), these mutations do not appear to be driving the disease, according to the results of a study from researchers at Fox Chase Cancer Center.

PHILADELPHIA (February 3, 2020) – Scientist and biostatistician Brian L. Egleston, MPP, PhD, of Fox Chase Cancer Center, will be teaming with scientists at the University of Pennsylvania on a series of studies that will attempt to develop methods for better communicating genetic test results to patients.

PHILADELPHIA (January 28, 2020) – The OCRA Liz Tilberis Early Career Award provides James Duncan, PhD, and seven other 2020 award winners with a three-year grant of $150,000 per year to support their research on ovarian cancer.

PHILADELPHIA (January 27, 2020) – Edna Cukierman, PhD, received a $292,999 grant from Worldwide Cancer Research for a two-year study of the microenvironment of pancreatic cancer cells.

PHILADELPHIA (January 23, 2020) – The three-year certification for oncology practices that meet nationally recognized standards for quality and safety in cancer care is recognized by the QOPI program, a wholly owned subsidiary of the American Society of Clinical Oncology (ASCO), builds on ASCO’s Quality Oncology Practice Initiative (QOPI).